With 1,000 Enrolled, Iverson Hoping to Report First Warfarin PGx Study Outcomes Data by End of 2015 | GenomeWeb

This article has been updated from an earlier version with additional information about the design and size of the WARFARIN trial. Additionally, Iverson has further clarified the difference between its study and the COAG trial.

MOUNTAIN VIEW, Calif. – By the end of 2015, Iverson Genetics is hoping to report final data from a large-scale prospective trial to determine whether genetic testing helps patients avoid serious adverse events associated with the highly variable anticoagulant warfarin.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.